ESR1 and breast cancer: These results highlight the urgency of exploring novel risk factors, such as genetics, epigenetics, biomarkers, and environmental exposures to understand the risk for less common but aggressive triple‐negative and ER/PR−HER2+ breast cancer subtypes, as existing risk factors appear largely irrelevant to risk of these tumors.